文献速递甲状腺疾病

无BRAFV600E时检出TERT启动子突变的甲状腺结节病理诊断:双中心52例系列

Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAFV600E: A Bi-Center Series of 52 Cases.
PubMed 文献 · Thyroid · 2025-07-28

该研究回顾性分析了两个学术医疗中心2323例行ThyroSeq检测的甲状腺结节患者,其中52例(2.3%)检出TERT启动子突变且无BRAFV600E共存。手术切除或活检诊断显示恶性风险为65%,但35%为良性/低风险肿瘤,提示存在过度治疗;高风险癌发生率在TERTp合并其他突变时显著增高。

要点

  • 无BRAFV600E的TERTp突变结节恶性风险为65%,但35%为良性/低风险肿瘤。
  • TERTp合并其他突变时高风险癌频率显著高于TERTp单独(48% vs 9.5%,p=0.006)。
  • 若无侵袭性临床或影像特征,腺叶切除可能足以作为初始管理。

核心结论

  • 35%的无BRAFV600E的TERTp突变结节为良性/低风险肿瘤,导致过度治疗。
  • TERTp突变结节中合并其他突变时高风险癌发生率增加。
  • 若惰性组织学在行为学层面得到确认,且无侵袭性临床或影像特征,腺叶切除可能足以作为初始管理。

研究设计与样本

  • 回顾性队列研究,纳入两个学术医疗中心2323例行术前细针穿刺ThyroSeq基因组分类检测的患者。
  • 共52例(2.3%)检出TERT启动子突变且无BRAFV600E共存。
  • 手术诊断来自切除标本(n=51)或活检(n=1,未分化甲状腺癌)。

主要发现

  • 恶性风险为65%。
  • 复习诊断:良性/低风险肿瘤18例(35%),癌-ATA低/中风险14例(27%),癌-ATA高风险20例(38.5%)。
  • 所有18例良性或低风险肿瘤均完整送检肿瘤包膜,78%行全甲状腺切除术。
  • 分子亚组:TERTp单独(n=21,40%)、TERTp+RAS(n=18,35%)、TERTp+其他非RAS突变(n=8,15%)、TERTp+RAS+其他改变(n=5,10%),恶性风险分别为57%、78%、50%、80%。
  • 高风险恶性肿瘤频率分别为9.5%、44.5%、37.5%、80%。

关键数值与推荐

  • 恶性风险65%(52例无BRAFV600E的TERTp突变结节)。
  • 良性/低风险肿瘤占35%(18/52)。
  • 癌-ATA低/中风险占27%(14/52),癌-ATA高风险占38.5%(20/52)。
  • TERTp单独恶性风险57%(n=21),TERTp+RAS 78%(n=18),TERTp+其他非RAS突变50%(n=8),TERTp+RAS+其他改变80%(n=5)。
  • TERTp合并其他改变 vs TERTp单独的高风险癌频率:48% vs 9.5%,p=0.006。

临床怎么用

  • 对无BRAFV600E的TERTp突变甲状腺结节,应认识到约35%为良性/低风险肿瘤,避免过度治疗。
  • 评估TERTp突变结节时需检测是否合并其他突变,合并其他突变者高风险癌可能性更高。
  • 若无侵袭性临床或影像特征,腺叶切除可能足以作为初始管理,避免全甲状腺切除术的副作用。

局限性

  • 回顾性研究设计。
  • 样本量较小(52例)。
  • 手术诊断主要来自切除标本(n=51),仅1例来自活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Mutations in the promoter region of TERT (TERTp) in thyroid nodules with indeterminate cytology are quoted to confer a high (∼80-95%) probability for thyroid carcinoma when detected on genomic classifier (GC) ThyroSeq. TERTp mutations may also occur in benign and low-risk thyroid neoplasms, and the risk of malignancy (ROM) in nodules harboring TERTp mutations without BRAFV600E is unknown. We analyzed the ROM and the surgical diagnosis in a retrospective cohort of thyroid nodules with TERTp treated at two academic medical centers. Methods: From 2323 patients with ThyroSeq GC performed on preoperative fine needle aspiration samples, 52 cases (2.3%) were identified harboring TERTp mutations without coexisting BRAFV600E. Results: The surgical diagnosis was obtained from resection (n = 51) or biopsy (n = 1, anaplastic thyroid carcinoma). The ROM was 65%. The reviewed diagnoses were benign/low-risk neoplasms in 18 (35%), carcinoma-American Thyroid Association (ATA) low/intermediate-risk in 14 (27%), and carcinoma-ATA high-risk in 20 (38.5%). All 18 benign or low-risk neoplasms had their tumor capsule submitted entirely, and 78% underwent total thyroidectomy. The molecular alterations were substratified into four groups: TERTp alone (n = 21, 40%), TERTp + RAS (n = 18, 35%), TERTp + other non-RAS mutation (n = 8, 15%), and TERTp + RAS + other alterations (n = 5, 10%), and the ROM for each group was 57%, 78%, 50%, and 80%, respectively. The frequency of a high-risk malignancy, which would often lead to a recommendation for total thyroidectomy, was 9.5%, 44.5%, 37.5%, and 80%, respectively. The frequency of high-risk carcinomas was significantly higher when a nodule harbored TERTp and other concomitant alterations (48%) compared with TERTp alone (9.5%; p = 0.006). Conclusions: Thirty five percent of TERTp nodules without BRAFV600E are benign/low-risk thyroid neoplasms, leading to their overtreatment. The incidence of high-risk carcinomas increases in TERTp-mutated nodules with the presence of additional mutations. If the indolent histology found in these lesions is confirmed at the behavior level, lobectomy may be sufficient for the initial management of TERTp thyroid nodules without BRAFV600E as long as there is no aggressive clinical or imaging feature. This will spare many patients from the side effects of total thyroidectomy.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Alzumaili BA, Instrum R, Alabkaa A, et al. Pathological Diagnosis of Thyroid Nodules with Preoperatively Detected TERT Promoter Mutations in the Absence of BRAFV600E: A Bi-Center Series of 52 Cases. Thyroid. 2025. PMID: 40720338. doi:10.1177/10507256251363450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。